Nov 12, 2008

It appears that stroke patients who receive both intravenous thrombolysis – a minimally invasive treatment that dissolves abnormal blood clots – and endovascular interventions – such as drugs and implanting medical devices – are much more likely to recover and have lower chances of dying, according to new research by the Zeenat Qureshi Stroke Research Center at the University of Minnesota Medical School.

Between 2003 and 2006, 33 consecutive patients with acute ischemic stroke –which occurs when a blood clot blocks an artery in the brain – were treated with thrombolysis in combination with endovascular interventions, which includes low doses of clot-fighting drugs and medical procedures such as angioplasty. The study looked at the outcomes of consecutive patients from a tertiary stroke facility where endovascular treatment was routinely available for patients treated with intravenous thromboysis. Outcomes were compared with a control cohort of 30 consecutive patients treated with thrombolysis at a comparable facility where endovascular interventions were not available.

Researchers found that the group that received both therapies experienced significantly lower mortality at 90 days (about 12 percent compared with 40 percent) with a significantly greater improvement in neurological ability by the time of discharge or follow-up. Patients younger than 80 years old showed the greatest improvement, with significant improvement in neurological deficits prior to treatment at the time of stroke.

The results were published in a recent issue of the American Journal of Neuroradiology.

"In theory it made sense to administer both treatments, but this is the first time we have the data to support the therapeutic benefit of such an approach," said Adnan I. Qureshi, M.D., executive director of the Stoke Initiative and Center at the University of Minnesota. "This is objective data to support the benefit of combination of intravenous thrombolysis and endovascular treatments."

Since the introduction of thrombolysis in the mid-1990s to clinical practice, no other treatment has been proved to further improve the clinical outcomes in patients with ischemic stroke – which is why this study is important, Qureshi said.

Since both thrombolysis and additional endovascular treatments are not available at all medical centers, Qureshi said the bigger implications of this study support the creation of specialized stroke centers – or designated stoke hospitals – for patients who have suffered a stoke so they can receive better care.

Related Stories

The only acute treatment for a stroke currently available is thrombolysis. This uses drugs that dissolve the blood clot responsible for the stroke, but it only reaches around 10 per cent of stroke patients in time to prevent ...

Among patients who have had strokes but aren't sure when symptoms began, magnetic resonance imaging (MRI) can help distinguish who might benefit from clot-busting drugs while facing acceptable risk, according to research ...

The largest clinical trial of therapeutic brain cooling (hypothermia) after stroke has launched, led by researchers at the University of California, San Diego, the University of Texas Health Science Center at Houston, and ...

Thrombolysis (giving anti-clotting drugs within three hours of an acute stroke) is effective in patients aged 40 to 90 years and should not be restricted in elderly patients, as current guidelines advise, concludes a study ...

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is ...

Patients with stroke who experience improvement within one hour of receiving the clot-dissolving medication tissue plasminogen activator appear more likely to do well three months later, according to a report in the November ...

Recommended for you

Since 2003, the H5N1 influenza virus, more commonly known as the bird flu, has been responsible for the deaths of millions of chickens and ducks and has infected more than 650 people, leading to a 60 percent ...

Drug-induced acute liver failure is uncommon, and over-the-counter medications and dietary and herbal supplements—not prescription drugs—are its most common causes, according to new research from the Perelman School of ...

ZMapp, the experimental Ebola drug that won notoriety when it was given to a handful of infected aid workers at the height of the epidemic, will now begin clinical testing in Liberian treatment centers, U.S. health authorities ...

Public health experts can identify nations that are vulnerable to the occurrence and impact of future outbreaks of Ebola or other emergencies by using a screening tool that evaluates a nation's strengths across a wide range ...

Vienna's public lavatories were at the focus of a study by the Global Food Safety research group at the Vetmeduni Vienna. The researchers studied 224 public restrooms in Vienna, which are about 91 percent ...

User comments : 0

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript.
In order to enable it, please see these instructions.